Identification of neoantigens for individualized therapeutic cancer vaccines
Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
Proteogenomic data and resources for pan-cancer analysis
Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer
The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk
transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed …
transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed …
[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
Non-viral precision T cell receptor replacement for personalized cell therapy
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
m6A RNA modifications are measured at single-base resolution across the mammalian transcriptome
Functional studies of the RNA N 6-methyladenosine (m6A) modification have been limited
by an inability to map individual m6A-modified sites in whole transcriptomes. To enable such …
by an inability to map individual m6A-modified sites in whole transcriptomes. To enable such …
Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
S Li, W Yu, F Xie, H Luo, Z Liu, W Lv, D Shi… - Nature …, 2023 - nature.com
Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …
[HTML][HTML] Proteogenomic characterization of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …
survival. Toward understanding the underlying molecular alterations that drive PDAC …
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …